Marco Oderda

[MolinetteUrology @UroMolinette]

Double live surgery day at @UroMolinette! ✌️😷
​2 simultaneous procedures performed:
✅ Kidney surgery connecting with @IrcadFrance
✅ Andrological live surgery
​Pushing the boundaries of urology. 🚀 @paolo_gontero @dottceruti @oderdam @giorgiocalleris @FedericoLavagno @medannot

[UroToday.com @urotoday]

Histopathologic features and transcriptomic signatures do not solve the issue of magnetic resonance imaging-invisible #ProstateCancers: a matched-pair analysis. #ProstateCancer invisibility on mpMRI ≠ indolence! A matched-pair study found no histopathologic or transcriptomic differences explaining MRI-invisible tumors—some still show aggressive features. #ReadNow > https://t.co/72KsSy5sLa @oderdam

[UroToday.com @urotoday]

Histopathologic features and transcriptomic signatures do not solve the issue of magnetic resonance imaging-invisible #ProstateCancers: a matched-pair analysis. #ProstateCancer invisibility on mpMRI ≠ indolence! A matched-pair study found no histopathologic or transcriptomic differences explaining MRI-invisible tumors—some still show aggressive features. #ReadNow > https://t.co/72KsSy5sLa @oderdam

[Marco Oderda @oderdam]

https://t.co/nlsocL8YuB
Interested in imaging of #radiorecurrent #prostatecancer? Watch this webinar!

[Federico Lavagno, MD @FedericoLavagno]

#TOP24 TURIN ONCOLOGY PROSTATE CANCER MASTERCLASS. FOR WHO IS INTERESTED IN ADVANCING KNOWLEDGE AND SKILLS IN THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER. 🗓️ 13/12
📍Turin, IT
📲 https://t.co/BvSjNctmDU
@paolo_gontero @UroMolinette @oderdam @GMarra_MD @peppinoiorio

[Marco Oderda @oderdam]

Happy to speak about #laparoscopic #inguinal #lymphadenectomy!

[Marco Falcone @drMarcoFalcone1]

Heading to #iMARS congress @AOUCareggi
Honored to present the second edition of our #andrology masterclass 💪🏽😎

@UroMolinette will actively involved with live surgeries, semi live and lectures 👏🏻

@paolo_gontero #marcooderda #mirkopreto @andrea_cocci @minerviniandre

[Over @OverEventi]

Grande partecipazione del pubblico ieri a Bari per NOW or NEVER – Il ruolo dell’#urologo nel trattamento multimodale del #CarcinomaProstatico, tra #Chirurgia e nuove terapie #Ormonali. Responsabili Scientifici Proff. A. Briganti
@Albert0Briganti e N. Suardi @urosuardi.
Docenti: M. Oderda, G. Procopio, M. Scarcia, G. Simone.
@oderdam @g_procopio_

[Prostate Cancer and Prostatic Diseases @pcan_journal]

🧬 Exciting new study shows how Prolaris genomic testing can help men with intermediate-risk #ProstateCancer make better treatment decisions! 📊 Patients recommended for Active Surveillance (AS) by Prolaris were 2x more likely to choose AS and 1.5x more likely to stay on it for 3 years. 🕒 #PrecisionMedicine #CancerResearch #MensHealth #Prolaris #Urology

[European Urology @EUplatinum]

Clincal and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer by Philip Sutera et al

Full article: https://t.co/gUuTh3Ah9y

#MedTwitter #UroSoMe #PCa #ProstateCancer

[MolinetteUrology @UroMolinette]

12-13-14/06 2024 ⤵️
🔎 Laparoscopy training course in Urology
📍 @unito @cittasalute_to
✅ Training simulation & live surgeries. We are ready 🙌 @paolo_gontero Lorenzo Repetto @PaoloDeste37946 @oderdam @Mat_Sibona Marco Allasia @FedericoLavagno CMerzagora MCatalano @SIU_Italia

[MolinetteUrology @UroMolinette]

Molinette Urology Equipe at @ab_medica for #SP #Davinci: @paolo_gontero @frasor86 @oderdam @p_deste

[MolinetteUrology @UroMolinette]

A great honor today for our family at @UroMolinette to have Prof. David Penson @urogeek with us in Turin! 🇮🇹🇺🇸 @paolo_gontero @umbertoricardi Prof.Albera Prof.ssa Cassoni @GMarra_MD @oderdam @frasor86 @MCalandri @cittasalute_to @unito @AmerUrological @VUMChealth

[Marco Oderda @oderdam]

@UroMolinette

[UroToday.com @urotoday]

Robot-assisted PSMA-radioguided surgery to assess surgical margins and nodal metastases in #ProstateCancer patients: Report on three cases using an intraoperative PET-CT specimen imager. #BeyondTheAbstract with @oderdam @cittasalute_to > https://t.co/5W2v4comUa @urogoldjournal

[Marco Oderda @oderdam]

@paolo_gontero @AMarquis_MD @UroMolinette Well deserved!

[Pawel Rajwa @dr_rajwa]

Secondary analysis of TITAN trial shows that half of patients with mHSPC treated with apalutamide who experienced radiographic progression developed it without corresponding PSA progression. Great team @jikei_urology @gehi87 @Keiichiro__Mori @DrShariat

https://t.co/e6jL7NmYdP

[MolinetteUrology @UroMolinette]

Day one with Prof. Jean De La Rosette has gone ✅
Such inspiring talks on BPH minimally invasive treatments 🤩👌
This is our team at @UroMolinette
lead by Prof. @paolo_gontero

@p_deste @frasor86 @GMarra_MD @Mat_Sibona @ marcoOderda @SIU_urology @cittasalute_to @unito

[Marco Falcone @drMarcoFalcone1]

Read our article @EurUrolOpen on inguinal lymphadenctomy for PeCa 😎
👉🏼 OILND vs VEILND
❌ comparable surgical outcomes
✅ VEILND quicker drain removal and less complications
👉🏼VEILND represents a safe technique

https://t.co/OATPlxP7b3
@paolo_gontero @docctoore @oderdam

[Romain Diamand @RomDiamand]

🆕 Transperineal or Transrectal MRI–targeted Biopsy for #ProstateCancer Detection

🎯 15 🇪🇺 centers - PSM 1301 matched pairs - @KoelisBx

💡ISUP2(3): 51% vs 45%; OR 1.37 (29% vs 23%; OR 1.38)

@JulesBordet @sb_uro @ESRUrology @Uroweb

https://t.co/6Fw4RI30xO

[SIU-Urology @SIU_urology]

🤝🩺 The Société Internationale d’Urologie (SIU) is pleased to support the Università di Torino in helping to disseminate its 3-minute survey to shed light on the current landscape of genetic testing and the use of PARP-inhibitors in different institutions. The answers will be acquired anonymously; the data will not be accessible to third parties and will be used only for scientific purposes.
🥼🧪 The subject of how and when to use genetic tests and PARP-inhibitors in prostate cancer has become one of the hot topics in urology. Not all the institutions and countries are prepared for the widespread use of genetic testing (somatic and/or germline) and not all have access to PARP-inhibitors in their routine clinical practice.
🔎 The insights gathered from this survey will play a crucial role in identifying gaps in current practices to help improve patient care and outcomes in prostate cancer management.

Answer the survey today! https://t.co/0ZCOEDebOW
*By answering the questions, you consent to the use of the data for scientific purposes.

Thank you for participating! #UroSoMe @unito @paolo_gontero @oderdam @StavrosGravas

[UroToday.com @urotoday]

Robot-assisted PSMA-radioguided surgery to assess surgical margins and nodal metastases in #ProstateCancer patients: Report on three cases using an intraoperative PET-CT specimen imager. #BeyondTheAbstract with @oderdam @cittasalute_to > https://t.co/5W2v4comUa @urogoldjournal